-
Cosmo Pharmaceuticals’ Lumeblue Completes Phase III Trial in China
•
Ireland-based Cosmo Pharmaceuticals N.V. (OTCMKTS: CMOPF) revealed that its Lumeblue (methylthioninium chloride) diagnostic agent has successfully completed a Phase III clinical trial in China. The trial was carried out by Cosmo’s partner, China Medical System Holdings Ltd (CMS; HKG: 0867). Trial Design and ResultsThe randomized, double-blind, placebo-controlled trial compared Lumeblue…
